The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma

Abstract

Complete cytoreduction is possible for the majority of patients with recurrent epithelial ovarian carcinoma and maximizes survival if undertaken before salvage chemotherapy. The authors believe a randomized trial should be initiated to confirm these findings.